OCGN Insider Trading

Insider Ownership Percentage: 4.29%
Insider Buying (Last 12 Months): $9,100.00
Insider Selling (Last 12 Months): $0.00

Ocugen Insider Trading History Chart

This chart shows the insider buying and selling history at Ocugen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Ocugen Share Price & Price History

Current Price: $0.68
Price Change: Price Increase of +0.0323 (4.99%)
As of 04/2/2025 03:39 PM ET

This chart shows the closing price history over time for OCGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.65Closing price on 04/01/25:

SEC Filings (Institutional Ownership Changes) for Ocugen (NASDAQ:OCGN)

10.27% of Ocugen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at OCGN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$3.03Mbought$651ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal InflowsTotal Outflows
Ocugen logo
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Read More on Ocugen

Today's Range

Now: $0.68
Low: $0.63
High: $0.71

50 Day Range

MA: $0.67
Low: $0.52
High: $0.80

52 Week Range

Now: $0.68
Low: $0.52
High: $2.08

Volume

2,449,561 shs

Average Volume

5,066,757 shs

Market Capitalization

$198.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.88

Who are the company insiders with the largest holdings of Ocugen?

Ocugen's top insider shareholders include:
  1. Junge Zhang (Director)
  2. Prabhavathi Fernandes (Director)
Learn More about top insider investors at Ocugen.